**Core Concept**
Chronic myeloproliferative disorders (CMPDs) are a group of clonal hematopoietic stem cell disorders characterized by excessive proliferation of one or more myeloid cell lines. The diagnosis and differential diagnosis of CMPDs rely on a combination of clinical presentation, laboratory findings, and molecular testing.

**Why the Correct Answer is Right**
Laboratory evaluation for CMPDs typically involves a complete blood count (CBC), bone marrow biopsy, and molecular testing. The CBC helps identify the specific myeloid cell line(s) involved and assesses the degree of proliferation. A bone marrow biopsy provides histological evidence of the disorder and helps determine the cell of origin. Molecular testing, such as Janus kinase 2 (JAK2) V617F mutation analysis, helps confirm the diagnosis of specific CMPDs like polycythemia vera (PV), essential thrombocytosis (ET), or primary myelofibrosis (PMF).

**Why Each Wrong Option is Incorrect**
**Option A:** Although not directly mentioned, other laboratory tests like erythropoietin levels and serum ferritin can also be useful in the evaluation of CMPDs.
**Option B:** Flow cytometry is a useful tool in the diagnosis of acute leukemias, but it is not typically used in the evaluation of CMPDs.
**Option C:** Peripheral blood smear examination is an essential part of the laboratory evaluation of CMPDs, as it can help identify specific morphological features associated with each disorder.

**Clinical Pearl / High-Yield Fact**
CMPDs are clonal disorders, and the JAK2 V617F mutation is present in a significant proportion of patients with PV, ET, and PMF. This mutation is thought to contribute to the development of these disorders by activating the JAK-STAT signaling pathway, leading to increased cell proliferation.

**Correct Answer: B. Flow cytometry is a useful tool in the diagnosis of acute leukemias, but it is not typically used in the evaluation of CMPDs.**